
NEWS RELEASE

Allowance of WaferiX™ Patent by United States Patent and Trademark Office Enhances Wafermine™ Intellectual Property Protection

- ✓ Second Notice of Allowance from US Patent and Trademark Office received in recent months
- ✓ Patent claims cover the WaferiX™ delivery technology and confers specific protection for Wafermine™, iX's lead drug under development

Singapore, 4 August 2020 – Specialty pharmaceutical company iX Biopharma Ltd (the “**Company**”), a late-stage specialty pharmaceutical company with a keen focus on the development of innovative therapies that improve the quality of life for those suffering from pain and other health conditions, is pleased to announce that the United States Patent and Trademark Office (“**USPTO**”) has issued a notice of allowance for its patent application entitled “Solid Dosage Form” (U.S. Patent Application No. 16/020,880). This is the second notice of allowance issued to iX Biopharma from the USPTO in recent months.

Upon issuance, the US patent is expected to expire no earlier than October 2030 and will provide key intellectual property protection for the Company's WaferiX™ delivery technology platform, and will provide a further barrier to generic entry in addition to the Company's notice of allowance for U.S. Patent Application No 13/504,309, which was issued earlier this year.

The allowed application contains composition of matter claims, which cover the WaferiX™ technology and provides specific protection for WaferiX™ delivering ketamine (Wafermine™). Wafermine™ is the Company's lead drug under development which is available for out-licensing. The Company has completed the End-of-Phase 2 meeting with the US FDA and reached an agreement with them on key aspects of the Phase 3 development for Wafermine™.

“We are very pleased to report this second notice of allowance in the United States”, commented Ms Eva Tan, iX Biopharma's Director of Corporate and Commercial Strategy. “The patent protection offers a strong barrier against competition with our WaferiX™ technology and allows Wafermine™ to have a substantial period of market exclusivity upon commercialisation. This Notice of Allowance is very timely as it increases Wafermine™'s attractiveness as an in-licensing asset to a potential partner.”

The communications from the USPTO conclude substantive examination of the patent application, which is now expected to be issued as a patent once the patent office concludes its administrative procedures.

The Company has also filed corresponding patent applications in other jurisdictions that will allow the Company to seek similar patent protection in other key markets throughout the world. The Company's intellectual property rights for its sublingual wafer technology is now secured in major markets including key markets of China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia, and Indonesia, countries in the European Union and others.

- End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

Contact for media:

Dr Janakan Krishnarajah

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com

Eva Tan

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: eva.tan@ixbiopharma.com

Investor Relations:

Kamal Samuel/James Bywater/Jonathan Wee

T: +65 6438 2990

E: Tech@financialpr.com.sg

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("**Sponsor**") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.